Skip to main content

Table 4 Further applications of the rocking motion bioreactor

From: Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy

Author - Year Type Cell Disease Target Expansion Functional highlights
Hami [98] - 2004 Pre-clinical T cell Chronic lymphocytic leukemia T cells from Chronic lymphocytic leukemia patients 400 fold in 13 days High in vitro activity and T cell receptor repertoire restored after expansion.
Hollyman [99] - 2009 Pre-clinical T cell Chronic lymphocytic leukemia T cells from Chronic lymphocytic leukemia patients 87–668 fold in 13–18 days Transduced and expanded T cells were able to eradicate the tumors in 90% of a mice population; release criteria were met
Andersen [109] - 2016 Clinical TIL Metastatic Melanoma Tumor-Infiltrating Lymphocytes from Patients with Metastatic Melanoma 2856–9975 fold in 13–36 days Tumor regression was achieved and associated with a higher absolute number of infused tumor-reactive T cells
Vavrova [101] - 2016 Pre-clinical T cell Prostate Cancer Prostate cancer reactive T cell effectors 6 fold in
8 days
Significantly greater cytotoxicity against LNCaP cells after expansion.
Bjoern [110] - 2017 Pre-clinical TIL Metastatic Melanoma Effect of Ipilimumab in metastatic melanoma derived T cells Ipilimumab induced marked changes in T cell infiltrates, which can still be detected despite heavy in vitro expansion.
O’hanlon [102] - 2017 Research T cell Non-specific 19F labeling for T cells Cellular viability was maintained; 90% of the T cell preparation was labeled with reagent